SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : North American Vaccine
NVX 0.910+4.6%Feb 6 9:30 AM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Don W Stone who wrote ()11/29/1997 7:49:00 AM
From: Don W Stone  Read Replies (1) of 507
 
Third Quarter 10Q: This is a very good document to read and reread if you have any second thoughts about what to do with NVX as we await imminent FDA approval.
What I interpret from it is that alot has been going on at NVX that just could come public very soon.
1) A new parnership or alliance
2) an acquisition
3) a major contract for business out of Abbott.
4) Results of other clinical trials or studies
And then as the 10Q implies,5) the long awaited FDA APPROVAL for DTaP.

I don't know if all of these have to neccesarily follow in the wake of the FDA approval.
In any event DECEMBER just could prove to be the month that Wall Street wakes up to the fact that NVX will be a very significant player in the fast growing international vaccine market.

Just perhaps friday was a good indicator of how the stock is going to behave. :-}, :-}, :-}, :-}, :-}, :-}, :-}.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News